MAGIC MUSHROOMS COULD TREAT PTSD AND DEPRESSION WITH NO SIDE EFFECTS
The active ingredient, psilocybin, did not have any negative side effects when administered in small doses
More people are using psychedelics to treat their mental health, according to the 2020 Global Drug Survey, which asked 110,000 people about their drug use. Some 6,500 people, almost six per cent, said they used recreational drugs to deal with mental health issues.
Thousands of people are now using drugs like LSD, MDMA, psilocybinand ketamine to deal with emotional issues and other mental health problems.
The report includes examples like individuals using very small doses of LSD or magic mushrooms on their own, or instances where psychedelics were used but under the watchful eye of another person yet still in a way that remained unregulated, Vice reported.
BUY MAGIC MUSHROOMS FOR MEDICAL PURPOSE
Supervisors were most often friends or partners of the person using a drug, but other settings included were psychedelic retreats or “traditional healing groups”.
Of those who reported having used psychedelics as a method to treat mental health issues, 72 per cent were men, 25 per cent were women, and two per cent said they were non-binary.
When you take psilocybin, your gut converts it into another chemical, known as psilocin, which binds to serotonin receptors called 2A, and experts think that’s what triggers what they call neuronal avalanching. It’s essentially a domino effect of different changes in the brain. You’ve got increased activity in the visual cortex, which leads to changes in your perception, and then decreased network activity in the default mode network, which leads to a loss of ego.
MAGIC MUSHROOMS TREATMENTS FOR PTSD
Small doses of magic mushrooms could help treat mental health conditions like PTSD, according to a new study.
Experts at the Institute of Psychiatry, Psychology & Neuroscience at King’s College London found that small amounts of psilocybin does not have short of long-term negative side effects in healthy people.
The authors of the small-scale study, published in The Journal of Psychopharmacology, found that psilocybin can be safely administered in either 10mg or 25mg doses.
Researchers believe that this initial trial, which had just 89 participants, could be a first step in proving the safety and feasibility of psilocybin as a treatment for mental health conditions like PTSD and depression.